Skip to content

Clinical Evaluation of the Cohera Sylys* Surgical Sealant as an adjunct to standard bowel anastomosis closure

Clinical Evaluation of the Cohera Sylys* Surgical Sealant as an adjunct to standard bowel anastomosis closure - PRO-106-0028

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39012
Enrollment
15
Registered
2013-03-20
Start date
2013-04-16
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stoma reversal

Interventions

Follow up: Clinical assessments will be performed pre-operatively, intra-operatively, during hospital stay, at discharge from hospital, at 7 days (± 1 days), 30 days (± 3 days) and 90 days (± 3 days

Sponsors

Cohera Medical
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Be at least 18 years of age; * Be in good general health in the opinion of the Investigator with no conditions that would significantly impact wound healing as determined by medical history and review of recent concomitant medications; * Be scheduled for an ileostomy reversal procedure; * Be willing to follow instructions for incision care; * Agree to return for all follow-up evaluations specified in this protocol; * Sign the informed consent.

Exclusion criteria

Exclusion criteria: * Anesthesia Risk judged to be higher than ASA2 * Have severe co-morbid conditions that pose a high risk for surgery and adequate recovery (e.g., heart disease) * Any condition involving compromised immune system * Any condition known to effect wound healing, such as collagen vascular disease * Known blood clotting disorder * Be receiving antibiotic therapy for pre-existing condition or infection * Concurrent use of fibrin sealants or other anastomosis care devices * Be currently taking systemic steroids or immunosuppressive agents * Have known or suspected allergy or sensitivity to any test materials or reagents * Be participating in any current clinical trial or have participated in any clinical trial within 30 days of enrollment in this study

Design outcomes

Primary

MeasureTime frame
Primary Endpoints Safety data will be gathered with respect to the number, timing, severity, duration and resolution of device related adverse events occurring among study subjects.

Secondary

MeasureTime frame
Secondary Endpoints * Length of hospital stay * Reoperation rate * Readmission rate * Number/type of additional procedures due to complications * Evaluation of the delivery method of the sealant Number of adverse events associated with known complications of ileostomy reversal. Known complications of ileostomy closure include: * Anastomotic leak * Wound infection * Intra-abdominal abscess/sepsis * Small bowel obstruction * Incisional hernia * Prolonged post-operative ileus * Post-operative enterocutaneous fistula

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)